اثر رژیم درمانی Taxotere/Xeloda در مبتلایان به سرطان پستان متاستاتیک

Background: Taxotere and Xeloda have been previously shown to be effective in metastatic breast cancer when prescribed as a single drug in addition, some studies have demonstrated their synergism in breast cancer. During the present study, we have used a combined Xeloda/Taxotere regimen in metastatic breast cancer patients who have never been on either drug. Materials and methods: Twelve breast cancer patients who have been on anthracycline regimen and had at least one measurable metastatic site were included. They were put on the following regimen: Taxotere 75mg/m2 for the first day and Xeloda 1000mg/m2 twice a day for 14 days. This protocol was repeated 3 times with 3 weeks interval between each phase. Metastatic sites were reevaluated following the course of therapy. Results: Of 12 patients, 4 have shown a complete response and 3 partial response. Myelosuppression was the most frequent drug side effect presenting in 5 patients. Conclusion: Combined regimen of Xeloda/Taxotere was found to be more effective than the single drug regimen. The side effects are acceptable.